Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, announced its participation in the Jefferies London Healthcare Conference on November 19-20, 2024. The company's management will conduct one-on-one meetings during both days and deliver a presentation on November 19 at 9:00 AM GMT. An audio webcast will be available in the Investors Section of Alvotech's website, with the recording accessible for 90 days post-event.
Alvotech (NASDAQ: ALVO), un'azienda biotech globale concentrata nello sviluppo di farmaci biosimilari, ha annunciato la sua partecipazione al Jefferies London Healthcare Conference che si terrà dal 19 al 20 novembre 2024. La direzione della società condurrà incontri individuali durante entrambi i giorni e presenterà una relazione il 19 novembre alle 9:00 GMT. Sarà disponibile un webcast audio nella Sezione Investitori del sito web di Alvotech, con la registrazione accessibile per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO), una empresa biotecnológica global enfocada en el desarrollo de medicamentos biosimilares, anunció su participación en la Jefferies London Healthcare Conference del 19 al 20 de noviembre de 2024. La dirección de la empresa llevará a cabo reuniones uno a uno durante ambos días y realizará una presentación el 19 de noviembre a las 9:00 AM GMT. Habrá un webcast de audio disponible en la Sección de Inversores del sitio web de Alvotech, con la grabación accesible durante 90 días después del evento.
알보텍 (NASDAQ: ALVO), 바이오시밀러 의약품 개발에 중점을 둔 글로벌 생명공학 회사가 2024년 11월 19일과 20일 제퍼리스 런던 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사 관리진은 양일간 개별 회의를 진행하고, 11월 19일 오전 9:00 GMT에 발표를 진행할 예정입니다. 알보텍 웹사이트의 투자자 섹션에서 오디오 웹캐스트가 제공되며, 이벤트 후 90일 동안 녹화본에 접근할 수 있습니다.
Alvotech (NASDAQ: ALVO), une entreprise biopharmaceutique mondiale axée sur le développement de médicaments biosimilaires, a annoncé sa participation à la Jefferies London Healthcare Conference qui se déroulera les 19 et 20 novembre 2024. La direction de l'entreprise organisera des réunions individuelles durant les deux jours et fera une présentation le 19 novembre à 9h00 GMT. Un webcast audio sera disponible dans la section Investisseurs du site web d'Alvotech, avec l'enregistrement accessible pendant 90 jours après l'événement.
Alvotech (NASDAQ: ALVO), ein globales Biotechnologieunternehmen, das sich auf die Entwicklung von biosimilaren Arzneimitteln konzentriert, gab seine Teilnahme an der Jefferies London Healthcare Conference am 19. und 20. November 2024 bekannt. Das Management des Unternehmens wird an beiden Tagen Einzelgespräche führen und am 19. November um 9:00 Uhr GMT eine Präsentation halten. Ein Audio-Webcast wird im Investorenbereich der Alvotech-Website verfügbar sein, mit einer Aufzeichnung, die 90 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT.
An audio webcast of the conference presentation will also be available to investors and the general public and can be accessed in the Investors Section of Alvotech’s website under News and Events – Events and Presentations. After the event, a recording will also be available for 90 days.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com.
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
FAQ
When is Alvotech (ALVO) presenting at the Jefferies London Healthcare Conference 2024?
How can investors access Alvotech's (ALVO) presentation at the Jefferies Conference?
What activities will Alvotech (ALVO) participate in during the Jefferies London Healthcare Conference 2024?
